https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=0
Page 0 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS: Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=1
Page 1 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE, HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS: Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. 2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=2
Page 2 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE, HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS: Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. 2 In another study, the incidence was found to be approximately 1%. 3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=3
Page 3 of 28
        "generic_name": [
          "NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE"
        "brand_name": [
          "Cortomycin"
 
      "adverse_reactions": [
        "Adverse Reactions Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. Leyden JJ and Kligman AM. Contact dermatitis to neomycin sulfate. JAMA. 1979; 242: 1276-1278. In another study, the incidence was found to be approximately 1%. Prystowsky SD, Allen AM, Smith RW, Nonomura JH, Odom RB, Akers WA. Allergic contact hypersensitivity to nickel, neomycin, ethylenediamine, and benzocaine: relationship between age, sex, history of exposure, and reactivity to standard patch and use tests in general population. Arch Dermatol. 1979; 115: 959-962. The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=4
Page 4 of 28
        "generic_name": [
          "NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE"
        "brand_name": [
          "Cortomycin"
 
      "adverse_reactions": [
        "Adverse Reactions Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. Leyden JJ. Kligman AM. Contact dermatitis to neomycin sulfate. JAMA 1979; 242: 276-1278. In another study, the incidence was found to be approximately 1%. Prystowsky SD, Allen AM, Smith RW, Nonomura JH, Odum RB, Akers WA. Allergic contact hypersensitivity to nickel, neomycin, ethylenediamine, and benzocaine: relationships between age, sex, history of exposure, and reactivity to standard patch tests and use tests in general population. Arch Dermatol 1979; 115:959-962. The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=5
Page 5 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "Adverse Reactions Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. Leyden JJ and Kligman AM. Contact dermatitis to neomycin sulfate. JAMA. 1979; 242: 1276-1278. In another study, the incidence was found to be approximately 1%. Prystowsky SD, Allen AM, Smith RW, Nonomura JH, Odom RB, Akers WA. Allergic contact hypersensitivity to nickel, neomycin, ethylenediamine, and benzocaine: relationship between age, sex, history of exposure, and reactivity to standard patch and use tests in general population. Arch Dermatol. 1979; 115: 959-962. The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=6
Page 6 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE, HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS: Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. 2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=7
Page 7 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=8
Page 8 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE, HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS: Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. 2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=9
Page 9 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported rarely when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=10
Page 10 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=11
Page 11 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=12
Page 12 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=13
Page 13 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE, HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS: Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see ). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. In another study, the incidence was found to be approximately 1%. WARNINGS 2 3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=14
Page 14 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported rarely when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=15
Page 15 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE, HYDROCORTISONE"
        "brand_name": [
          "Antibiotic Ear (Neo/Polym/HC)"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS: Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. 2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=16
Page 16 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS ). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported rarely when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=17
Page 17 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS ). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported rarely when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=18
Page 18 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS ). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported rarely when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=19
Page 19 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE, HYDROCORTISONE"
        "brand_name": [
          "NEOMYCIN and POLYMYXIN B SULFATES and HYDROCORTISONE"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS: Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. 2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=20
Page 20 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=21
Page 21 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS ). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported rarely when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=22
Page 22 of 28
        "generic_name": [
          "NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE"
        "brand_name": [
          "NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS SECTION Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=23
Page 23 of 28
        "generic_name": [
          "NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS: Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=24
Page 24 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE, HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS: Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. 2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=25
Page 25 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE, HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS: Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. 2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=26
Page 26 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
https://api.fda.gov/drug/label.json?api_key=mIN5BAt8Q4kciIz367SmtW9t6aWsj0oF6bafJBOd&search=generic_name:Neomycin+AND+and+AND+Polymyxin+AND+B+AND+Sulfates+AND+and+AND+Hydrocortisone+AND+Otic+AND+Solution&limit=1&skip=27
Page 27 of 28
        "generic_name": [
          "NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE"
        "brand_name": [
          "Neomycin and Polymyxin B Sulfates and Hydrocortisone"
 
      "adverse_reactions": [
        "ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS ). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.2 In another study, the incidence was found to be approximately 1%.3 The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear."
 
 
--------------------------------------------------------------------------------------------------------------------
